Key statistics
As of last trade, AIM ImmunoTech Inc (HXB2:DUS) traded at 0.23, 29.21% above the 52 week low of 0.178 set on Oct 03, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.23 |
---|---|
High | 0.23 |
Low | 0.23 |
Bid | 0.23 |
Offer | 0.248 |
Previous close | 0.236 |
Average volume | 0.00 |
---|---|
Shares outstanding | 63.32m |
Free float | 57.86m |
P/E (TTM) | -- |
Market cap | 16.59m USD |
EPS (TTM) | -0.5703 USD |
Data delayed at least 15 minutes, as of Oct 09 2024 08:10 BST.
More ▼
Announcements
- AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis
- AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering
- AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
- AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
- AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue
- AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
- AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment
- AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
More ▼